Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology During IVF/ICSI
Status:
Recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
Selection of developmentally competent oocytes enhances IVF efficiency. Usually, oocyte
quality is determined based on its nuclear maturation and the presence of specific
cytoplasmic and extracytoplasmic morphologic features. Gonadotropin-releasing hormone
agonists (GnRH Agonists) and gonadotropin-releasing hormone antagonists (GnRH Antagonists)
are used during controlled ovarian stimulation (COS) protocols in order to prevent premature
luteinizing hormone (LH) surge and premature ovulation. However, GnRH receptors are also
expressed in extra-pituitary tissues such as ovary, but it is still unknown whether the type
of GnRH analogues used during COS could affect the oocyte morphology, especially with the
limited and conflicted currently available data. Thus, we are conducting this prospective,
non-randomised, open-label, clinical trial to compare the effects of two pituitary
suppression regimens; GnRH Agonist-Long Protocol and GnRH Antagonist-Flexible Protocol on
oocyte morphology during IVF/ICSI.